Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

Despite the tremendous advances in the treatment of multiple myeloma, mortality remains significant, highlighting the need for new effective strategies. In recent years, daratumumab, a novel human monoclonal antibody, binding CD38, has dramatically improved outcomes either as monotherapy or in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dima, Danai, Dower, Joshua, Comenzo, Raymond L, Varga, Cindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457558/
https://www.ncbi.nlm.nih.gov/pubmed/32904669
http://dx.doi.org/10.2147/CMAR.S212526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457558/
https://www.ncbi.nlm.nih.gov/pubmed/32904669
http://dx.doi.org/10.2147/CMAR.S212526

Ejemplares similares